Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial

(2020) Seth B. Forman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors

(2020) Rajesh Bahekar et al.   BIOORGANIC CHEMISTRY

Applicability of a Modified Rat Model of Acute Arthritis for Long-Term Testing of Drug Delivery Systems

(2019) Imke Rudnik-Jansen et al.   Pharmaceutics

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

(2019) Stephen T. Wrobleski et al.   JOURNAL OF MEDICINAL CHEMISTRY

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update

(2019) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

(2018) Claire N Harrison et al.   Lancet Haematology

Inborn Errors of Human JAKs and STATs

(2012) Jean-Laurent Casanova et al.   IMMUNITY

Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)

(2009) Christopher J. Burns et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success

(2009) Frank Lovering et al.   JOURNAL OF MEDICINAL CHEMISTRY

Intracellular signal pathways: Potential for therapies

(2009) Melissa Mavers et al.   Current Rheumatology Reports